Immunogenicity of the therapeutic proteins

Drug Discovery World

Volumn 7, Issue 3, 2006, Pages 94-98

  Van Walle, Ivo ^a   Lasters, Ignace ^a   Stas, Philippe ^a,b  

^a Algonomics   (Belgium)

^b FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; EPITOPE; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A33; PROTEIN DERIVATIVE; RITUXIMAB; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; CHIMERA; COMPUTER MODEL; CYTOTOXIC T LYMPHOCYTE; DRUG EXPOSURE; ENZYME LINKED IMMUNOSPOT ASSAY; ETHNOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; NONHODGKIN LYMPHOMA; NONHUMAN; PREDICTION; PREVALENCE; PROTEIN BINDING; REVIEW; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

EID: 33746919545     PISSN: 14694344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (8)

1. Mire-Sluis, AR et al. J Immunol Methods. 289(1-2):1-16, 2004.
2. Koning, F. Gastroenterology 129: 1294-1301, 2005.
3. Singh, H and Raghava, GP. Bioinformatics 17:1236-1237, 2001.
4. Reche, PA et al. Immunogenetics 56:405-419, 2004.
5. Desmet, J et al. Proteins 58:53-69, 2005.
6. Koren, E et al. Curr Pharm Biotechnol 3:349-360, 2002.
7. Harding, F. Clin Exp Allergy 33:557-565, 2003.
8. Hwang, W and Foote, J. Methods 36:3-10, 2005.